Department of War Pharmacy Uniform Formulary Blanket Purchase Agreement/Uniform Formulary Additional Discount Program

The Defense Health Agency Aurora, on behalf of the TRICARE Management Activity, has issued solicitation HT9402-26-Q-9203 to establish an integrated pharmacy benefits program for the Military Health System. In accordance with 10 U.S.C. § 1074g and 32 CFR Section 199.21, the Department of War Pharmacy and Therapeutics (P&T) Committee evaluates the clinical and cost effectiveness of pharmaceutical agents to determine their placement on the Uniform Formulary. This solicitation seeks quotes for specific drug classes to facilitate the award of Uniform Formulary Blanket Purchase Agreements and Uniform Formulary Additional Discount Program Agreements. The May 2026 P&T Committee meeting will specifically review newly approved drugs including Arynta, Atmeksi, Avtozma, Desmoda, Foundayo, Icotyde, Kygevvi, Lerochol, Loargys, and Yuviwel.

Performance is centered in San Antonio, Texas, under NAICS code 325412 for Pharmaceutical Preparation Manufacturing and PSC 6505 for Drugs and Biologicals. The solicitation process includes a pre-quotation teleconference scheduled for April 15, 2026, with all formal responses due by April 27, 2026. Submissions must include clinical evaluations and pricing data as specified in the request for quotation and its associated appendices.

Documentation for this opportunity consists of 14 attachments, including various price lists for growth stimulating agents, metabolic agents, and antilipidemics, as well as guidance on the placement of newly approved drugs. Stephanie Erpelding serves as the primary point of contact for this requirement. Detailed instructions for electronic submission of clinical questions and quotation components are provided within the formal RFQ materials.